Drug manufacturers Johnson & Johnson and Astellas Pharma have each asked federal district courts to strike down parts of the [...] …
Articles by : William Newton, Associate Editor/Senior Writer
The U.S. Senate Finance Committee could mark up a pharmacy benefit manager reform bill next week with Medicaid managed care [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The U.S. Chamber of Commerce asked a federal district court in Ohio last week to stop Medicare from implementing the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
On a sunny, humid, 92-degree afternoon in Washington, D.C., over 50 safety-net health care providers marched to the U.S. Capitol [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
It could be “truly catastrophic” if two federal appeals courts rule as a third did in January that drug manufacturers [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Apexus, the federally contracted 340B prime vendor, and AIDS Healthcare Foundation are meeting with a mediator to try to settle [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The National Rural Health Association has intensified its 340B advocacy work with a new congressional campaign and set of policy [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Maine Gov. Janet Mills (D) signed bipartisan legislation late last week requiring 340B hospitals to submit annual reports consistent with the American Hospital Association’s voluntary 340B good stewardship principles.
The new law made Maine the second state to impose reporting
…
ASAP 340B, the nonprofit group that the brand drug industry and health centers formed to help advance the two sides’ joint plan to remake the 340B program, held its first webinar yesterday to describe its policy principles and call for
…
Hospitals that enrolled in the 340B program after its expansion in 2010 treated more commercially insured cancer patients with five commonly prescribed biologic oncology drugs and spent more on the drugs, a new JAMA study found.
The authors of